Synthetic Biologics announces positive outcome of end-of-phase 2 meeting with FDA
Synthetic Biologics announced it has successfully completed an End-of-Phase 2 meeting with the FDA to discuss development of SYN-004 (ribaxamase) for prevention of antibiotic-mediated Clostridium difficile infection. The FDA has proposed criteria for Phase 3 clinical efficacy and safety. November 21, 2018